Figures & data
Figure 1. The effect of brain tumour-derived EVs on endothelial cells. EVs derived from primary and metastatic brain tumour cells can deliver angiogenic proteins and miRNAs and promote an angiogenic phenotype in endothelial cells.
Figure 2. The effect of brain tumour-derived EVs on immune cells. EVs derived from primary brain tumour cells can induce an M2 phenotype in microglia and decrease the cytotoxicity of the CD8 + T cells. Metastatic brain tumour EVs can activate microglia through the TLR receptor.
Figure 3. The effect of brain tumour-derived EVs on brain-specific cells. Astrocytes can be affected by EVs from primary and metastatic brain tumours. Astrocyte-derived EVs can affect breast cancer brain metastasis through decreasing the PTEN expression.
Figure 4. The effect of brain tumour-derived EVs on extracellular matrix. EVs derived from primary and metastatic brain tumour cells can increase the degradation of extracellular matrix directly through activation of tPA and indirectly via an increase in expression of MMPs.
